Abstract
Interferon has been used to treat chronic viral hepatitis and several malignancies. However, it may cause various neuropsychiatric adverse effects including parkinsonism. We report a rare case of interferon alpha-2a therapy-related parkinsonism in a 67-year-old man with metastatic papillary renal cell carcinoma and our experience of using Tc-99m-TRODAT-1 single photon emission computed tomography (SPECT) as a tool for evaluation of parkinsonism. Physicians should be alert to the possibility of interferon alpha-2a-related parkinsonism.
MeSH terms
-
Aged
-
Brain / diagnostic imaging*
-
Brain / pathology
-
Diagnosis, Differential
-
Humans
-
Immunologic Factors / administration & dosage
-
Immunologic Factors / adverse effects
-
Interferon alpha-2
-
Interferon-alpha / administration & dosage
-
Interferon-alpha / adverse effects*
-
Male
-
Organotechnetium Compounds
-
Parkinsonian Disorders / chemically induced*
-
Parkinsonian Disorders / diagnosis
-
Parkinsonian Disorders / diagnostic imaging
-
Parkinsonian Disorders / pathology
-
Recombinant Proteins / administration & dosage
-
Recombinant Proteins / adverse effects
-
Tomography, Emission-Computed, Single-Photon / methods
-
Tropanes
Substances
-
Immunologic Factors
-
Interferon alpha-2
-
Interferon-alpha
-
Organotechnetium Compounds
-
Recombinant Proteins
-
Tropanes
-
technetium Tc 99m TRODAT-1